PEB Pacific Edge Limited
—Mkt Cap: —P/E: —Today
Pacific Edge Limited, a cancer diagnostics company, engages in development and commercialization of bladder cancer diagnostic and prognostic tests for patients. It operates through two segments, Commercial and Research. …
Industry Peers
Biotechnology$128.87BUSDP/E 29.6
$94.42BUSD
$81.99BUSDP/E 19.1
$53.47BUSDP/E 32.5
$53.22BUSDP/E 31.6
$44.02BUSDP/E 17.8
$42.56BUSDP/E 66.4
$40.57BUSD
$34.45BUSDP/E 30.4
$31.32BUSDP/E 39.3
$24.59BUSD
$23.32BUSDP/E 31.7
$23.26BUSDP/E 29.8
$22.96BUSDP/E 14.0
$22.66BUSD
$21.67BUSD
$15.57BUSDP/E 19.3
$14.91BUSDP/E 17.4
$13.92BUSDP/E 14.7
$13.79BUSDP/E 33.4
Key Statistics
Company
Market Cap—
Enterprise Value130.96M USD
Revenue (TTM)7.29M USD
Gross Profit6.44M USD
Net Income (TTM)-20.04M USD
Revenue/Share0.01 NZD
Last Price—
Fiscal Year EndMar 2026
MR QuarterMar 2026
Employees—
CountryNZ
SectorHealthcare
IndustryBiotechnology
ISINNZPEBE0002S1
Valuation
P/E (Trailing)—
P/E (Forward)-19.93
PEG—
EV/EBITDA-6.59
EV/Revenue17.97
P/S22.91
P/B24.00
EPS (TTM)-0.04
EPS (Forward)-0.01
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin100.00%
Oper. Margin-274.34%
EBITDA Margin-272.67%
Profit Margin-311.14%
ROE-335.66%
ROA-203.26%
Growth
Revenue Growth-45.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-17.89M USD
CapEx (TTM)73.93K USD
FCF Margin-147.26%
FCF Yield—
Net Debt-3.64M USD
Net Debt/EBITDA0.18
Balance Sheet
Debt/Equity0.12
Current Ratio2.02
Quick Ratio1.50
Book Value/Sh0.01 NZD
Cash/Share0.0080 NZD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 NZD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)0.2000 NZD
Target Range0.2000 NZD – 0.2000 NZD
# Analysts1
Ownership
Shares Out.1.24B
Float853.81M
Insiders19.72%
Institutions30.16%
Technical
SMA 500.2535 NZD
SMA 2000.2330 NZD
Beta0.84
S&P 52W Chg16.44%
Avg Vol (30d)—
Avg Vol (10d)1.00M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—